Yaohai Bio-Pharma to Showcase End-to-End Microbial CRDMO Solutions at BIO International Convention 2026 in San Diego Yaohai Bio-Pharma will attend the upcoming BIO International Convention
NANJING, China, May 28, 2026 — Yaohai Bio-Pharma congratulates its strategic partner, Beijing Northland Biotechnology Co., Ltd. (“Northland Bio”), on the NMPA approval of Donaperminogene
Yaohai Bio-Pharma has once again been recognized as a leading innovator in the global biopharmaceutical industry. During the 2026 Future Healthcare 100 Conference held on
Yaohai Bio-Pharma will participate in Swiss Biotech Day 2026, one of Europe’s most influential biotechnology events. The conference will take place on May 4–5, 2026,
Yaohai Bio-Pharma is a leading CRDMO specializing in microbial expression systems. We offer end-to-end purification process development, starting from primary purification and moving all the
Yaohai Bio-Pharma provides integrated, end-to-end microbial fermentation services under the highest global GMP standards. With this combination of technology and experience, we become a reliable
Yaohai Bio-Pharma operates a cutting-edge microbial CRDMO platform built on E. coli and yeast expression systems. In addition, we offer one-stop microbial cell banking solutions
Yaohai Bio-Pharma has more than 15 years of experience in microbial cell line development and cell bank construction. Microbial cell line development and high-yield strain
Yaohai Bio-Pharma, a leading CRDMO focused on microbial expression systems, has announced the launch of its new microbial biologics platform. This platform brings together more
